Siponimod (brand name: Mayzent) is a selective sphingosine-1-phosphate (S1P) receptor modulator being investigated for repurposing in Alzheimer's Disease at St. Joseph's Hospital. This trial (NCT06639282) evaluates the safety and efficacy of siponimod in patients with early to moderate AD, leveraging its immunomodulatory properties to target neuroinflammation—a key pathological driver of neurodegeneration[@josephs].
Siponimod is already approved by the FDA for treating relapsing forms of multiple sclerosis (MS), where it demonstrates robust efficacy in reducing disease activity and disability progression[@fda2019].
Siponimod is a selective S1P receptor modulator that primarily targets:
S1P1 receptor: Predominantly expressed on lymphocytes
Internalizes and degrades S1P1 receptors, preventing lymphocyte egress from lymphoid tissues
Reduces circulating pro-inflammatory lymphocytes that can infiltrate the CNS
Decreases CNS immune cell infiltration
S1P5 receptor: Expressed on astrocytes and oligodendrocytes
Modulates glial cell function
Promotes oligodendrocyte survival and myelination
May support neuronal protection
Key Molecular Mechanisms
...
Overview
Siponimod (brand name: Mayzent) is a selective sphingosine-1-phosphate (S1P) receptor modulator being investigated for repurposing in Alzheimer's Disease at St. Joseph's Hospital. This trial (NCT06639282) evaluates the safety and efficacy of siponimod in patients with early to moderate AD, leveraging its immunomodulatory properties to target neuroinflammation—a key pathological driver of neurodegeneration[@josephs].
Siponimod is already approved by the FDA for treating relapsing forms of multiple sclerosis (MS), where it demonstrates robust efficacy in reducing disease activity and disability progression[@fda2019].
Siponimod is a selective S1P receptor modulator that primarily targets:
S1P1 receptor: Predominantly expressed on lymphocytes
Internalizes and degrades S1P1 receptors, preventing lymphocyte egress from lymphoid tissues
Reduces circulating pro-inflammatory lymphocytes that can infiltrate the CNS
Decreases CNS immune cell infiltration
S1P5 receptor: Expressed on astrocytes and oligodendrocytes
Modulates glial cell function
Promotes oligodendrocyte survival and myelination
May support neuronal protection
Key Molecular Mechanisms
Mermaid diagram (expand to render)
Neuroprotective Effects
Beyond immune modulation, siponimod may provide direct neuroprotection through:
Astrocyte modulation: S1P5 receptor signaling influences astrocyte reactivity and function
Oligodendrocyte support: Promotes survival and function of myelin-producing cells
Neurotrophic effects: S1P signaling can support neuronal survival pathways
Blood-brain barrier integrity: May improve BBB function and reduce leakiness
Rationale for Alzheimer's Disease
Neuroinflammation in AD
Alzheimer's Disease is characterized by:
Amyloid-beta (Aβ) plaques: Accumulation of misfolded Aβ peptides
Neurofibrillary tangles: Hyperphosphorylated tau protein aggregates
Neuroinflammation: Chronic activation of microglia and astrocytes
Synaptic dysfunction: Loss of neuronal connections
Neuroinflammation is now recognized as both a consequence and driver of AD pathology. Activated microglia release pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) that:
Exacerbate amyloid deposition
Promote tau pathology
Accelerate synaptic loss
Contribute to cognitive decline
Why S1P Modulation?
The S1P pathway is implicated in AD through multiple mechanisms:
Microglial activation: S1P receptors regulate microglial phenotype and function
Unknown, St. Joseph's Hospital. Siponimod for Alzheimer's Disease. ClinicalTrials.gov NCT06639282 (n.d.)
Unknown, FDA. Mayzent (siponimod) prescribing information (2019)
[Kappos L, et al, Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study (2018)](https://pubmed.ncbi.nlm.nih.gov/29519765/)
[Choi JW, et al, FTY720 (fingolimod) is a sphingosine 1-phosphate receptor antagonist that suppresses experimental autoimmune encephalomyelitis (2005)](https://pubmed.ncbi.nlm.nih.gov/15824544/)
[van Doorn R, et al, Sphingosine 1-phosphate receptor 1 and 5 in the central nervous system (2010)](https://pubmed.ncbi.nlm.nih.gov/20553957/)
[imov J, et al, Role of sphingosine-1-phosphate signaling in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32731040/)
[Domeniconi G, et al, S1P receptor modulators in multiple sclerosis: a review of emerging data (2020)](https://pubmed.ncbi.nlm.nih.gov/31916055/)